Medtronic Widens MRI-Compatible Portfolio After FDA Approval Of StrataMR Shunt System

Medtronic plc MDT revealed the FDA clearance of StrataMR valves and shunts, an addition to its family of Strata Adjustable Valve Systems used in the treatment of patients with hydrocephalus and cerebrospinal fluid (CSF) disorders. According to the company, the StrataMR system was planned to maintain its performance level setting during magnetic resonance imaging (MRI) exposure when scanned in accordance with labeling.

Medtronic indicated the clearance adds to its portfolio of systems meant for access to full-body MRI, like pacemakers, implantable cardioverter defibrillators (ICDs), deep brain stimulation (DBS) systems, and spinal cord stimulators. The company stated that the StrataMR system would be available to physicians, as well as, their patients in the coming months.

Medtronic's CSF Management unit Marketing Director, Tom Poss, said that "Patients with hydrocephalus and CSF disorders often require MRI. The use of MRI has become a diagnostic standard of care, allowing physicians to detect a wide range of health conditions. And our StrataMR technology will offer healthcare providers a level of confidence in the shunt's performance should an MRI become necessary."

Commenting on the developments, Professor of Neurosurgery at Utah University, Marion Walker, said "I see many implications for the use of the new StrataMR, especially with patients who need to have their valves re-checked after MR imaging. Also, this technology will benefit those patients who are concerned about their exposure to strong magnets. This new technology may cut down on some of the insecurities these patients may feel."

On Monday, the stock traded 1.02 percent higher.